Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

被引：0
作者：
Luca Manetti
Timo Deutschbein
Jochen Schopohl
Kevin C. J. Yuen
Michael Roughton
Ulrike Kriemler-Krahn
Libuse Tauchmanova
Ricardo Maamari
Carla Giordano
机构：
[1] Università di Pisa,Azienda Ospedaliero
[2] University of Würzburg,Universitaria Pisana, Dipartimento di Medicina Clinica e Sperimentale
[3] Ludwig-Maximilians-Universität München,Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital
[4] Swedish Neuroscience Institute,Medizinische Klinik und Poliklinik IV
[5] Barrow Neurological Institute,Swedish Pituitary Center
[6] Novartis Pharma AG,Section of Endocrinology, Diabetology and Metabolism, Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities (PROMISE)
[7] Novartis Pharmaceuticals Corporation,undefined
[8] University of Palermo,undefined
来源：
Pituitary | 2019年 / 22卷
关键词：
Cushing’s disease; Pasireotide; Hypercortisolism; Pituitary; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：542 / 551
页数：9
相关论文
共 154 条
[51]  
Boscaro M(undefined)undefined undefined undefined undefined-undefined
[52]  
Pivonello R(undefined)undefined undefined undefined undefined-undefined
[53]  
Pivonello R(undefined)undefined undefined undefined undefined-undefined
[54]  
Petersenn S(undefined)undefined undefined undefined undefined-undefined
[55]  
Newell-Price J(undefined)undefined undefined undefined undefined-undefined
[56]  
Findling J(undefined)undefined undefined undefined undefined-undefined
[57]  
Gu F(undefined)undefined undefined undefined undefined-undefined
[58]  
Maldonado M(undefined)undefined undefined undefined undefined-undefined
[59]  
Trovato A(undefined)undefined undefined undefined undefined-undefined
[60]  
Hughes G(undefined)undefined undefined undefined undefined-undefined
12345678910